(Q47944425)

7 February 2018

title

The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy. (English)

1 reference

7 February 2018

0 references

Horwitz EM

1

1 reference

7 February 2018

Hanlon AL

series ordinal

2

1 reference

7 February 2018

Pinover WH

series ordinal

3

1 reference

7 February 2018

Hanks GE

series ordinal

4

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 June 1998

1 reference

7 February 2018

International Journal of Radiation Oncology Biology Physics

published in

1 reference

7 February 2018

volume

41

1 reference

7 February 2018

issue

3

1 reference

7 February 2018

page(s)

519-523

1 reference

7 February 2018

Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/ml

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

Analyzing predictive models following definitive radiotherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

Late GI and GU complications in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2898%2900095-9

7 January 2021

10.1016/S0360-3016(98)00095-9

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

9635697

1 reference

7 February 2018